WP2 - Formulation, development and preparation of a paediatric oral solution

The following objectives are addressed in the present WP:

•    to develop and prepare a drug product suitable for the paediatric population with a small weight range
•    to develop a -80 mg/mL oral solution that is more palatable than the one currently on the market

WP Leader: John Connelly (Apotex)
Involved Partners: CVBF, ApoPharma, Apotex, UKER